{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T18:32:57Z","timestamp":1754159577547,"version":"3.41.2"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"DOI":"10.7759\/cureus.88734","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T14:17:24Z","timestamp":1753453044000},"source":"Crossref","is-referenced-by-count":0,"title":["Rapidly Progressive Kidney Disease in a Patient With IgA Nephropathy and Focal Segmental Glomerulosclerosis Due to Nonadherence and Loss to Follow-Up"],"prefix":"10.7759","author":[{"given":"Zaheeruddin","family":"Sayed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Bellot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier  J","family":"Mendoza Mulen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy","volume":"368","author":"Wyatt RJ","year":"2013","unstructured":"Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013, 368:2402-14. 10.1056\/NEJMra1206793","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford classification of IgA nephropathy 2016: an\u00a0update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi H","year":"2017","unstructured":"Trimarchi H, Barratt J, Cattran DC, et al.. Oxford classification of IgA nephropathy 2016: an\u00a0update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017, 91:1014-21. 10.1016\/j.kint.2017.02.003","journal-title":"Kidney Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen T","year":"2015","unstructured":"Rauen T, Eitner F, Fitzner C, et al.. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015, 373:2225-36. 10.1056\/NEJMoa1415463","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-6386(97)90456-x","article-title":"Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases","volume":"29","author":"Haas M","year":"1997","unstructured":"Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis. 1997, 29:829-42. 10.1016\/s0272-6386(97)90456-x","journal-title":"Am J Kidney Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017090958","article-title":"Differentiating primary, genetic, and secondary FSGS in adults: a clinicopathologic review","volume":"29","author":"De Vriese AS","year":"2018","unstructured":"De Vriese AS, Sethi S, Nath KA, Glassock RJ, Fervenza FC. Differentiating primary, genetic, and secondary FSGS in adults: a clinicopathologic review. J Am Soc Nephrol. 2018, 29:759-74. 10.1681\/ASN.2017090958","journal-title":"J Am Soc Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.63","article-title":"Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments","volume":"86","author":"Coppo R","year":"2014","unstructured":"Coppo R, Troyanov S, Bellur S, et al.. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014, 86:828-36. 10.1038\/ki.2014.63","journal-title":"Kidney Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstr\u00f6m BC","year":"2017","unstructured":"Fellstr\u00f6m BC, Barratt J, Cook H, et al.. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017, 389:2117-27. 10.1016\/S0140-6736(17)30550-0","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette R","year":"2023","unstructured":"Lafayette R, Kristensen J, Stone A, et al.. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023, 402:859-70. 10.1016\/S0140-6736(23)01554-4","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich HN","year":"2007","unstructured":"Reich HN, Troyanov S, Scholey JW, Cattran DC. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007, 18:3177-83. 10.1681\/ASN.2007050526","journal-title":"J Am Soc Nephrol"},{"key":"ref10","article-title":"Factors predicting progression of IgA nephropathies","volume":"18","author":"Coppo R","year":"2005","unstructured":"Coppo R, D'Amico G. Factors predicting progression of IgA nephropathies. J Nephrol. 2005, 18:503-12.","journal-title":"J Nephrol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/367957-rapidly-progressive-kidney-disease-in-a-patient-with-iga-nephropathy-and-focal-segmental-glomerulosclerosis-due-to-nonadherence-and-loss-to-follow-up","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T14:17:25Z","timestamp":1753453045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/367957-rapidly-progressive-kidney-disease-in-a-patient-with-iga-nephropathy-and-focal-segmental-glomerulosclerosis-due-to-nonadherence-and-loss-to-follow-up"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.88734","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,25]]}}}